NovaBay Pharmaceuticals, Inc. (NBY) earnings
NBY earnings moved a median of -3.29% by the close. Quarterly and annual NBY reports and results, each read against the price at its own news timestamp. Back to the NBY overview →
19 measured NBY earnings events.
Where these NBY earnings landedvs 19 measured NBY earnings reactions
| Middle 50% of NBY earnings reactions | -4.44% to -0.68% |
|---|---|
| Median reaction (to close) | -3.29% |
| Measured reactions | 19 |
Point-in-time · zero look-ahead
Half of the 19 NBY earnings events with a measured close landed between -4.44% and -0.68%; 21% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-K NovaBay Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | +0.00% | -4.92% | |
| Form 10-Q NovaBay Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-Q | -2.78% | +0.00% | |
| Form 10-Q NovaBay Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | -0.70% | +5.92% | |
| Form 10-Q NovaBay Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | -0.56% | -1.84% | |
| Form 10-K NovaBay Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | +0.00% | -1.35% | |
| Form NT 10-K NovaBay Pharmaceuticals, For: Dec 31 | SEC filing · Form NT | +0.00% | +0.02% | |
| Form 10-Q NovaBay Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-Q | -1.39% | -3.58% | |
| NovaBay Pharmaceuticals Reports Third Quarter 2024 Financial Results | Press release | -1.39% | -3.58% | |
| Form 10-Q NovaBay Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | -1.81% | -3.29% | |
| NovaBay Pharmaceuticals Reports Second Quarter 2024 Financial Results | Press release | -1.81% | -3.29% | |
| NovaBay Pharmaceuticals to Hold Second Quarter 2024 Conference Call on August 13, 2024 | Press release | -0.02% | -8.52% | |
| NovaBay Pharmaceuticals Reports Preliminary Second Quarter 2024 Net Revenue of $2.4 Million | Press release | +0.46% | +3.24% | |
| Form 10-Q NovaBay Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | -3.00% | -7.16% | |
| NovaBay Pharmaceuticals Reports First Quarter 2024 Financial Results | Press release | -3.00% | -7.16% | |
| Form 10-K/A NovaBay Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | -0.28% | -1.96% | |
| Form 10-K NovaBay Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | -4.39% | -14.25% | |
| Form 10-Q NovaBay Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-Q | -0.99% | -3.96% | |
| NovaBay Pharmaceuticals Reports Third Quarter 2023 Financial Results | Press release | -0.99% | -3.96% | |
| NovaBay Pharmaceuticals to Hold Third Quarter 2023 Conference Call on November 9, 2023 | Press release | -0.26% | +3.99% |
Keep exploring
More NBY: analyst actions → · SEC filings → · NBY overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Pediatrix Medical Group, Inc. (MD) | 206 | +0.02% | 51% |
| Curis, Inc. (CRIS) | 205 | 0.00% | 45% |
| OptiNose, Inc. (OPTN) | 205 | 0.00% | 48% |
| ASPEN PHARMACRE HL UN/ADR (APNHY) | 204 | 0.00% | 15% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.